| Immunotherapy is changing the treatment landscape for specific subsets of pediatric cancer patients. |
| Several monoclonal antibodies are FDA approved for patients with hematologic malignancies but only one is FDA approved for patients with solid tumors; checkpoint inhibition therapy is FDA approved in very limited subsets of pediatric patients, such as those with melanoma, Hodgkin lymphoma, and biallelic mismatch repair deficiency. |
| Chimeric antigen receptor T cell (CAR-T) therapy is FDA approved for some pediatric patients with leukemia but challenges remain in leveraging such technology for patients with solid tumors. |
| Issues of importance are the investigation of combinations of immunotherapies, the identification of predictive biomarkers, and specific toxicities of immunotherapies in pediatric patients. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.